eli lilly news - Search News

Honda, Nissan, Novo Nordisk, Eli Lilly

YAHOO!Finance · 5h

Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for investors.

Barron's on MSN · 3d

Eli Lilly, Novo Nordisk Stocks Rise. Only One Is Operating From a Position of Strength.

The obesity drug race is heating up in more ways than one.Eli Lilly, the world’s biggest pharmaceutical company by market value, benefited from some good news Friday.The Food and Drug Administration approved Lilly’s blockbuster drug for weight-loss Zepbound to also treat sleep apnea,

Benzinga.com · 3d

Eli Lilly Stock Is Rising Monday: What's Going On?

Eli Lilly and Company (NYSE: LLY) shares are trading higher Monday. The upward momentum in the stock comes after the FDA approved the company's Zepbound, a weight loss drug designed to treat moderate-to-severe obstructive sleep apnea in adults with obesity.

Wall Street Journal · 3d

Stocks to Watch Monday: Honda, Nissan, Novo Nordisk, Eli Lilly

The Motley Fool on MSN · 3d

Better Buy: Eli Lilly or Novo Nordisk?

In this video, I will cover the recent updates regarding Novo Nordisk (NYSE: NVO) and whether or not the dip is worth buying over Eli Lilly (NYSE: LLY). Watch the short video to learn more, consider subscribing,

Zepbound, obstructive sleep apnea and Eli Lilly

The FDA just approved Eli Lilly's Zepbound for sleep apnea — and Medicare coverage could be next

Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug Administration (FDA) as the first prescription drug to help alleviate moderate-to-severe obstructive sleep apnea (OSA) for adults with obesity.

The Wall Street Journal on MSN · 3d

Eli Lilly Gets FDA Approval for Zepbound for Certain Sleep Apnea Patients

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

Newsable Asianet News on MSN · 1d

Weight loss drug Zepbound gets US FDA nod to treat sleep apnea; India launch expected in 2025

In a groundbreaking move, the US Food and Drug Administration (FDA) has approved the anti-diabetic drug Zepbound, also known as Tirzepatide, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity.

Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

1don MSN

Eli Lilly & Co. stock underperforms Tuesday when compared to competitors

Shares of Eli Lilly & Co. LLY sank 0.08% to $795.67 Tuesday, on what proved to be an all-around favorable trading session for ...

7d

This Is Huge News for Eli Lilly Investors

Eli Lilly just gave investors several reasons to cheer.

3d

Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports

In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs ...

7hon MSN

Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic

CEO's newfound preference for Eli Lilly's (NYSE:LLY) weight loss therapy Mounjaro over Novo Nordisk's (NVO) rival product ...

8d

Eli Lilly Is Putting Dividend Growth Stocks to Shame With Yet Another Huge Increase to Its Payout

What Eli Lilly ( LLY -0.05%) is doing is far more impressive. The company has been increasing its dividend at a high rate, ...

6h

Elon Musk's Weight-Loss Secret Shakes Up Pharma Giants

Novo Nordisk and Eli Lilly face soaring demand--and stiff competition--as obesity drug market transforms healthcare and ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results